Beigene Ltd (NASDAQ:BGNE) price target lowered to $170.00 by Piper Jaffray Companies

ME Staff
-
0

Analyst Ratings For Beigene Ltd (NASDAQ:BGNE)

Today, Piper Jaffray Companies lowered its price target on Beigene Ltd (NASDAQ:BGNE) to $170.00 per share.

There are 10 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Beigene Ltd (NASDAQ:BGNE) is Buy with a consensus target price of $174.9688 per share, a potential 25.00% upside.

Some recent analyst ratings include

  • 1/3/2019-Beigene Ltd (NASDAQ:BGNE) had its Buy rating reiterated by Maxim Group with a $170.00 price target
  • 11/28/2018-Beigene Ltd (NASDAQ:BGNE) has coverage initiated with a Overweight rating and $174.00 price target
  • 11/7/2018-Beigene Ltd (NASDAQ:BGNE) had its Buy rating reiterated by Cowen
  • 9/24/2018-Beigene Ltd (NASDAQ:BGNE) has coverage initiated with a Outperform ➝ Outperform rating and $215.00 price target
  • 9/19/2018-Beigene Ltd (NASDAQ:BGNE) has coverage initiated with a Buy rating and $160.75 price target
  • 9/17/2018-Beigene Ltd (NASDAQ:BGNE) has coverage initiated with a Buy rating
  • On 12/18/2018 Amy C Peterson, CMO, sold 20,000 with an average share price of $133.68 per share and the total transaction amounting to $2,673,600.00.
  • On 12/10/2018 John Oyler, CEO, sold 4,138 with an average share price of $135.78 per share and the total transaction amounting to $561,857.64.
  • On 12/3/2018 Xiaodong Wang, Director, sold 5,000 with an average share price of $152.41 per share and the total transaction amounting to $762,050.00.
  • On 11/28/2018 John Oyler, CEO, sold 29,195 with an average share price of $143.66 per share and the total transaction amounting to $4,194,153.70.
  • On 11/26/2018 Jane Huang, CMO, sold 3,000 with an average share price of $139.58 per share and the total transaction amounting to $418,740.00.
  • On 11/26/2018 John Oyler, CEO, sold 9,078 with an average share price of $139.06 per share and the total transaction amounting to $1,262,386.68.
  • On 11/19/2018 Xiaodong Wang, Director, sold 5,000 with an average share price of $124.30 per share and the total transaction amounting to $621,500.00.

About Beigene Ltd (NASDAQ:BGNE)
BeiGene, Ltd. develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia. The company's clinical stage drug candidates include BGB-3111, a small molecule Bruton's tyrosine kinase (BTK) inhibitor for the treatment of lymphomas; BGB-A317, a humanized monoclonal antibody for solid and hematological cancers; BGB-290, a small molecule inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway; BGB-A333, an humanized monoclonal antibody for the immune checkpoint receptor ligand PD-L1; and MGCD-0516, a multi-kinase inhibitor. Its preclinical programs consists of therapies and immuno-oncology agents, including an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company has strategic collaborations with Celgene Corporation to research and develop BeiGene, Ltd.'s investigational anti-programmed cell death protein 1 inhibitor, BGB-A317; Merck KGaA to research and develop on BGB-290 and BGB-283; and MEI Pharma, Inc. to evaluate the safety and efficacy of ME-401, an investigational PI3K delta inhibitor in combination with BeiGene's zanubrutinib, an investigational BTK inhibitor for the treatment of patients with B-cell malignancies. BeiGene, Ltd. was founded in 2010 and is based in George Town, the Cayman Islands.

Recent Trading Activity for Beigene Ltd (NASDAQ:BGNE)
Shares of Beigene Ltd closed the previous trading session at 139,97 −0,050 0,036 % with 139.93 shares trading hands.